Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X MSCI Argentina ETF (ARGT) vs TransMedics Group Inc (TMDX) Price & Performance

Global X MSCI Argentina ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Global X MSCI Argentina ETF vs TransMedics Group Inc — how do they compare? Global X MSCI Argentina ETF trades at $91.07, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

ARGTTMDX
Sector
Broad Market / FactorTechnology
52-Week High
$102.94$150.42
52-Week Low
$67.55$61.99
Market Cap
$3.10B
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X MSCI Argentina ETF

ARGT is trading at $91.95, down 1.58% today amid bearish technical signals. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $92. Recent Seeking Alpha analysis (June 18, 2026) highlights Argentina's economic reforms creating potential for 28% upside, though financial ratios remain undisclosed. The fund's concentration in MercadoLibre presents both opportunity and risk as Argentina's monetary backdrop improves.

The outlook suggests cautious optimism with reform progress driving potential re-rating, though technical weakness and single-country concentration require careful risk management. Near-term performance hinges on Argentina's economic stabilization and institutional investor confidence, with Stanley Druckenmiller's recent position (Q1 2026) indicating sophisticated investor interest.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX